Journal article
NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma
SR Mattarollo, AC West, K Steegh, H Duret, C Paget, B Martin, GM Matthews, J Shortt, M Chesi, PL Bergsagel, M Bots, J Zuber, SW Lowe, RW Johnstone, MJ Smyth
Blood | Published : 2012
Abstract
Immunomodulators are effective in controlling hematologic malignancy by initiating or reactivating host antitumor immunity to otherwise poorly immunogenic and immune suppressive cancers. We aimed to boost antitumor immunity in B-cell lymphoma by developing a tumor cell vaccine incorporating (α-galactosylceramide (α-GalCer) that targets the immune adjuvant properties of NKT cells. In the Eμ-myc transgenic mouse model, single therapeutic vaccination of irradiated, (α-GalCer-loaded autologous tumor cells was sufficient to significantly inhibit growth of established tumors and prolong survival. Vaccine-induced antilymphoma immunity required NKT cells, NK cells, and CD8 T cells, and early IL-12-d..
View full abstractGrants
Awarded by National Institute on Aging
Funding Acknowledgements
This work was supported by the National Health and Medical Research Council of Australia (program grant). S.R.M. was supported by a Balzan Foundation Fellowship. M.J.S. was supported by a National Health and Medical Research Council of Australia Fellowship.